CX Institutional
NBIX icon

CX Institutional’s Neurocrine Biosciences NBIX Stock Holding History

CX Institutional’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18K Hold
126
– – ﹤0.01% 1258
2026
Q2 		$21K Hold
126
– – ﹤0.01% 1167
2026
Q1 		$17K Buy
+126
New +$16.7K ﹤0.01% 1161

Other funds holding NBIX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
PKO BP Bankowy Universal Pension Society
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CX Institutional's NBIX Position: Q3 2026 in Review

CX Institutional held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 126 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

CX Institutional first reported a position in NBIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $21K in Q2 2026. 143 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • CX Institutional held 126 shares of Neurocrine Biosciences worth $18K as of Q3 2026.
  • CX Institutional left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1258 holding.
  • CX Institutional first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 3 quarters since.
  • CX Institutional's Neurocrine Biosciences position peaked at $21K in Q2 2026.
  • 143 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.